目的 测定人血浆中泮托拉唑的浓度，并评价国产和进口泮托拉唑钠肠溶片的生物等效性。方法 采用LC-MS/MS测定人血浆中泮托拉唑的浓度，以DAS2.0计算药动学参数考察其生物等效性。结果 受试制剂和参比制剂的泮托拉唑t_1/2分别为（1.96±0.66）和（1.98±0.59）h，t_max分别为（3.17±0.84）和（3.09±0.81）h，ρ_max分别为（3.53±0.78）和（3.41±0.79）μg·mL^-1，AUC_0-∞分别为（10.12±4.09）和（10.86±3.99）μg·h·mL^-1。生物利用度为（97.9±22.3）%。结论 该方法重复性好，灵敏度高，泮托拉唑钠肠溶片受试制剂和参比制剂具有生物等效性。

OBJECTIVE To determine the concentration of pantoprazole in human plasma and evaluate the bioequivalence of two kinds of pantoprazole sodium enteric-coated tablets. METHODS The concentration of pantoprazole in human plasma was determined by LC-MS/MS， and the pharmacokinetic parameters for evaluation of bioequivalence were calculated with DAS2.0. RESULTS The main pharmacokinetic parameters of test and reference formulation were as followst_1/2 (1.96±0.66) and (1.98±0.59) h， (3.17±0.84) and (3.09±0.81) h， ρ_max (3.53±0.78) and (3.41±0.79) μg·mL^-1， AUC_0-∞ (10.12±4.09) and (10.86±3.99) μg·h·mL^-1. The relative bioavailability was （97.9±22.3）%. CONCLUSION The method is repeatable and sensitive. The test and reference formulation are bioequivalent.